@article{5281,
  keywords = {Biomarker, Education, Immune related adverse event - irAE, Immunotherapy, statistics},
  author = {Riyue Bao and Alan Hutson and Anant Madabhushi and Vanessa D. Jonsson and Spencer R. Rosario and Jill S. Barnholtz-Sloan and Elana J. Fertig and Himangi Marathe and Lyndsay Harris and Jennifer Altreuter and Qingrong Chen and James Dignam and Andrew J. Gentles and Edgar Gonzalez-Kozlova and Sacha Gnjatic and Erika Kim and Mark Long and Martin Morgan and Eytan Ruppin and David Van Valen and Hong Zhang and Natalie Vokes and Daoud Meerzaman and Song Liu and Eliezer M. Van Allen and Yi Xing},
  title = {Ten challenges and opportunities in computational immuno-oncology},
  abstract = {Immuno-oncology has transformed the treatment of cancer, with several immunotherapies becoming the standard treatment across histologies. Despite these advancements, the majority of patients do not experience durable clinical benefits, highlighting the imperative for ongoing advancement in immuno-oncology. Computational immuno-oncology emerges as a forefront discipline that draws on biomedical data science and intersects with oncology, immunology, and clinical research, with the overarching goal to accelerate the development of effective and safe immuno-oncology treatments from the laboratory to the clinic. In this review, we outline 10 critical challenges and opportunities in computational immuno-oncology, emphasizing the importance of robust computational strategies and interdisciplinary collaborations amid the constantly evolving interplay between clinical needs and technological innovation.},
  year = {2024},
  journal = {Journal for ImmunoTherapy of Cancer},
  volume = {12},
  pages = {e009721},
  month = {2024/10/01},
  issn = {2051-1426},
  url = {https://jitc.bmj.com/content/12/10/e009721},
  doi = {10.1136/jitc-2024-009721},
  language = {en},
}